drug

RAP-219

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 3 registered trials in coverage

Relationships

Developed by Rapport Therapeutics Inc.

Timeline

Rapport Therapeutics advances RAP-219 Phase 3 epilepsy program in Q2 2026

Aug 5Quarterly updateRAP-219 Rapport Therapeutics Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.